Taking HRT alongside tirzepatide: the clinical picture

Why NHS England singled out oral HRT in its tirzepatide guidance

Tirzepatide is a dual GIP and GLP-1 receptor agonist, the only medicine of its kind licensed in the UK for weight management. One of its mechanisms is slowing the rate at which the stomach empties its contents into the small intestine. For most people this is part of why the treatment reduces appetite and promotes a feeling of fullness. But it also means that any medicine absorbed in the upper gut, including oral tablets, may spend longer in the stomach before it reaches the site where absorption happens.

NHS England's guidance on weight-management injections specifically flags this for oral HRT. The concern is not that HRT becomes dangerous; it is that the effective dose reaching your bloodstream could be lower than intended, potentially leaving symptoms undertreated. Women who are stable on an oral HRT regimen and then start tirzepatide may find their symptom control changes, not because of a direct hormonal interaction, but because of altered absorption.

Transdermal preparations (patches applied to the skin or gels rubbed in once daily) bypass the digestive system entirely. Because they deliver hormones through the skin directly into the bloodstream, gastric emptying has no bearing on how much you absorb. This is why the NHS specifically points toward these forms rather than recommending HRT be stopped.

What the guidance means in practice for women already on HRT

If you are currently taking oral HRT tablets and are considering tirzepatide, the conversation to have is with your GP or the clinician managing your HRT, before you start treatment. They can review whether switching to a patch or gel is appropriate for you, taking into account your symptom history, the specific hormones you are taking, and any other health factors.

For women already established on transdermal HRT, there is no equivalent concern flagged in NHS guidance. Patches and gels are unaffected by changes in gastric emptying, so the absorption picture stays consistent regardless of tirzepatide use.

It is also worth noting that if you are using oral contraceptives rather than HRT, the guidance is slightly different again, tirzepatide's summary of product characteristics advises adding a non-oral contraceptive method for the first four weeks of treatment and for four weeks after each dose increase, because pill absorption can also be reduced. The detailed position on HRT specifically with Mounjaro draws on the same underlying pharmacology.

None of this represents a reason to avoid tirzepatide if HRT is part of your daily routine. It represents a reason to plan the transition thoughtfully, with both your prescribers talking to each other if needed.

Starting tirzepatide when you are on HRT: the clinical assessment at nume

Every person who applies for tirzepatide through nume has their consultation read by a GPhC-registered Independent Prescriber, a real clinician, not a form-sorting algorithm. Your current medicines, including HRT, are part of that review. The prescriber looks at what you are taking, the route of administration, and whether any adjustments should be discussed before treatment begins.

If your HRT is already transdermal, or if you have already switched in conversation with your GP, the pathway is straightforward. If you are on oral tablets and that review has not happened yet, our prescribers will flag this and can advise on next steps, including whether to loop in the clinician who manages your HRT. This is not a bureaucratic hurdle; it is the kind of joined-up clinical thinking that matters when combining treatments.

Once a prescription is issued, the medicine is dispatched from our GPhC-registered pharmacy the same working day for orders confirmed before 12pm. Your pen arrives the next working day via DPD, in plain unbranded packaging, the tracking notification goes to your phone before it reaches your door. You can read more about tirzepatide's mechanism and licensed use in the UK if you want a fuller picture before your consultation.

A note on monitoring and ongoing care

The HRT-and-tirzepatide question does not end at the first prescription. As your dose of tirzepatide increases over the titration schedule, gastric emptying slows further at higher doses, and if you want to understand how specific formulations behave across the range, our guide covering tirzepatide's licensed doses and how they are used sets this out in detail. If you are on oral HRT and have not switched formulations, this is worth keeping in mind at each review: symptom changes that feel hormonal may have an absorption component.

NHS England's guidance also notes the importance of telling your healthcare team (including your GP and any specialist) that you are taking a GLP-1 medicine, particularly before any surgical procedure where the anaesthetist needs a complete drug history. Some people also ask about specific health conditions in the context of weight management treatment, and our page on tirzepatide and MS is a useful example of the kind of condition-specific guidance we provide. If you want to explore how tirzepatide is priced and what a private prescription covers, that context may be useful as you weigh your options. For questions our prescribers hear regularly about living with tirzepatide day-to-day, the FAQs page covers the practical ground. The MHRA's Yellow Card scheme is also there if you ever want to report a suspected side effect.

When you are ready to take the next step, speaking to our prescribers is the right place to start, they can look at your full clinical picture, including your current HRT, and give you a clear answer about suitability. Start your free consultation to speak to our prescribers today.